OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Arnold on the Evaluation of Chemo With Amivantamab or Cetuximab in RAS/BRAF Wild-Type mCRC

June 19th 2025

Dirk Arnold, MD, PhD, on the investigation of amivantamab vs cetuximab, both in combination with chemotherapy, in RAS/BRAF wild-type mCRC.

Dr Markman the Significance of PROs in Patients With Locally Advanced Cervical Cancer

June 19th 2025

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Dr Chung on the Potential Role for Ficerafusp Alfa Plus Pembrolizumab in the HPV-Negative HNSCC Paradigm

June 18th 2025

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma

June 18th 2025

Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

Dr Cristofanilli on the Next Steps With Camizestrant in HR+/HER2– Breast Cancer

June 18th 2025

Massimo Cristofanilli, MD, discusses the next steps with camizestrant in ESR1-mutated HR-positive, HER2-negative advanced breast cancer.

Dr Landgren on the Efficacy of Dara-KRd in Newly Diagnosed Myeloma Regardless of Transplant Eligibility

June 18th 2025

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Dr Komrokji on the Effect of Prior Treatment on Imetelstat Activity in Transfusion-Dependent LR-MDS

June 18th 2025

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

Dr Gasparini on Challenges With Oral Therapies in Pediatric Patients or Patients With Dysphagia

June 18th 2025

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Dr Lin on the Rationale for Evaluating Cilta-Cel–Associated Late-Onset Toxicities in Myeloma

June 18th 2025

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Paulus on Factors Contributing to Earlier Onset of CRC in Younger Patients

June 17th 2025

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

Dr Duska on the Adoption of Pembrolizumab Plus Concurrent CRT as a SOC in Advanced Cervical Cancer

June 17th 2025

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Dr Tan on Important Considerations for Nivolumab/Ipilimumab Selection in Metastatic ccRCC

June 17th 2025

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Dr Starr on the Rationale for Targeting DLL3 in Extrapulmonary Neuroendocrine Carcinomas

June 17th 2025

Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.

Dr D'Amato on the Implications of Data With Olaparib Plus Temozolomide in Advanced Uterine Leomyosarcoma

June 16th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Dr Mehta on the Mitigation of Common Immunotherapy-Related Toxicities in Urothelial Cancer

June 16th 2025

Amit Mehta, MD, outlines the common toxicities encountered with immunotherapy-containing regimens in urothelial cancer and strategies to mitigate them.

Dr Munir on the Efficacy of First-Line Zanubrutinib vs Acalabrutinib Plus Venetoclax in CLL

June 16th 2025

Tahla Munir, MBChB, PhD, details the efficacy of first-line zanubrutinib and clinical implications for treatment selection in CLL.

Dr McKay on Data for Olaparib Plus Radium-223 in CRPC With Bone Metastases

June 16th 2025

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.

Dr Krishnan on the Potential Clinical Impact of Trispecific Antibodies in R/R Multiple Myeloma

June 16th 2025

Amrita Krishnan, MD, discusses the potential clinical impact of trispecific antibodies in the management of relapsed/refractory multiple myeloma.

Dr Scarfò on Updated Safety Data With BGB-16673 in Relapsed/Refractory CLL/SLL

June 15th 2025

Lydia Scarfò, MD, discusses long-term data with BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma

June 15th 2025

Meletios A. Dimopoulos, MD, discusses efficacy and safety findings with elranatamab plus daratumumab and lenalidomide in newly diagnosed multiple myeloma.